PulseSight Therapeutics

Recent Finacing

Seed

Recent Raise

Undisclosed

PulseSight Therapeutics develops non-viral plasmid gene therapies delivered via a minimally invasive ciliary muscle platform for wet and dry AMD, with PST-809 and PST-611 in IND‑enabling development.

Founded 2008

Ile-de-France, France

11-50

Private

pulsesight.com

Highlights

Focus Areas

Biotechnology

Medical

Therapeutics

Recent Investors

Financials

1

Funding round

3

Investors

Team

Upgrade to view the team

See the team members at PulseSight Therapeutics.